United States Pharmacopeia (USP)

United States Pharmacopeia (USP) is a non-governmental, nonprofit organization engaged in setting standards for drug quality and safety. It is governed by the USP Convention, including 450 academic institutions, healthcare organizations and patient and government groups, with 900 independent advisory experts. USP standards for sterile and non-sterile compounding of drug products are widely adopted and used by state regulators and the healthcare industry. Currently, USP is in the process of updating its standards on drug compounding.

New Chapter <797> Revisions

Pharmacopeia released its proposed revisions to USP General Chapter <797> Pharmaceutical Compounding –Sterile Preparations for a second round of public comment. General Chapter <797> provides standards for compounding quality sterile preparations.

Since the first public comment period, which began in September 2015, USP has gathered significant stakeholder input from roundtable meetings, discussion forums, and review of more than 8,000 written public comments. To supplement the review, expert consultants have been engaged to assist the Expert Committee during the revision process.

In response to initial comments, USP extended the beyond-use dates (BUDs) for compounded sterile preparations (CSPs), but even so the proposed one-size-fits-all BUDs remain too short. As proposed, even when a CSP is tested, it cannot be used beyond 60 days frozen/45 days refrigerated from the date compounded. ASRS again cautioned USP that making stock items such as cyclosporine and tacrolimus is going to be nearly impossible. The sterility tested BUD is so restrictive that some compounders may elect to avoid testing and just use the Non-Tested BUD (45 days frozen/4 days refrigerated). In our second set of comments [insert], ASRS again urged USP to retain the language in the current version of 797 which allows BUDs to be extended based on the scientific literature or through product-specific experimental studies. The status quo would also ensure that the USP 797 guidelines are in synchrony with FDA guidance which allows testing to determine BUDs.

USP aims to publish the final revised Chapter on December 1, 2019. We are hopeful that USP will stick with science to avert serious cost and access implications for ophthalmologists and patients alike.

FDA Comment Letters

Advocacy Timeline

Designed and built in Chicago by Webitects